Apr 06, 2020
HEMA Biologics(TM) Announces FDA Approval of SEVENFACT® [coagulation factor VIIa (recombinant)-jncw] for Treatment and Control of Bleeding Episodes Occurring in Adult and Adolescent Hemophilia A and B Patients with Inhibitors
Apr 01, 2020
FDA Approves Additional Treatment for Adults and Adolescents with Hemophilia A or B and Inhibitors
Jul 19, 2019
Bayer statement on voluntary recall of two lots of Kogenate® FS antihemophilic factor (recombinant) in the United States
Jul 01, 2019
CSL Behring Delivers on its Promise to Advance Bleeding Disorder Treatment Research by Supporting 16 Data Presentations at ISTH 2019
Jun 18, 2019
Health Canada Approves Hemlibra® for Hemophilia A Patients Without Factor VIII Inhibitors
May 21, 2018
Head-to-head pharmacokinetic study demonstrated greater factor IX activity with Rebinyn® versus rFIXFc in people with hemophilia B
Apr 20, 2018
Prime Therapeutics Finds Costs Double When Switching to New Extended Half-Life Hemophilia Factor Products
Apr 16, 2018
Grifols donates over 25 million international units of blood clotting factor in 2017
Apr 11, 2018
Novo Nordisk launches Rebinyn®, a new, long-acting treatment for patients with hemophilia B in Canada
Feb 12, 2018
Research Study Results Presented at EAHAD 2018
Feb 08, 2018
Novo Nordisk Launches Rebinyn® in the United States for People with Hemophilia B
Feb 07, 2018
Time to Elevate Protection in Haemophilia Care: New Data From Sobi(TM)
Feb 07, 2018
The Republic of Ireland Switches all People With Haemophilia A & B Treated With Replacement Clotting Factors to Sobi's(TM) Extended Half-life Therapies
Oct 27, 2017
The First Patient Enrolled in the ReITIrate Study Evaluating Immune Tolerance Induction With Elocta®
Oct 25, 2017
Sobi: Alprolix® Approved in the Kingdom of Saudi Arabia for the Treatment of Haemophilia B
Jun 27, 2017
EMA Approves the Potential to Dose Every 14 Days or Longer in Updated Dosing Regimen for Alprolix®
May 31, 2017
FDA Approves New Novo Nordisk Treatment for Patients with Hemophilia